Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ORIC, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Rinzimetostat (ORIC-944) | Metastatic Castration Resistant Prostate Cancer | Phase 3 · NCT07723248 | Recruiting |
| Enozertinib (ORIC-114) | Solid Tumors | Phase 1/2 · NCT05315700 | Recruiting |
| Nab-paclitaxel | Solid Tumor | Phase 1 · NCT03928314 | Terminated |
| CD73 Inhibitor ORIC-533 | Relapsed or Refractory Multiple Myeloma | Phase 1 · NCT05227144 | Completed |
| Glucocorticoid Receptor Antagonist ORIC- | Prostatic Neoplasms | Phase 1 · NCT04033328 | Terminated |
Also used in these trials (approved or third-party drugs, not ORIC's own candidates): Darolutamide, Docetaxel Anhydrous, Enzalutamide, Carboplatin, Amivantamab, Abiraterone Acetate, Apalutamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ORIC holds $387.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $32M/quarter from operations, an estimated runway of 36.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
We expect our current cash, cash equivalents and investments will be sufficient to fund our current operating plan into the second half of 2028.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORIC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | Institution (13G, 5%+) | 8,264,607 | 7.97% | 2026-03-31 |
| Nextech Invest, Ltd. | Institution (13F) | 7,162,637 | 6.91% | 2026-06-30 |
| EcoR1 Capital, LLC | Institution (13F) | 6,728,116 | 6.49% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,473,145 | 5.28% | 2025-12-31 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 5,387,783 | 5.20% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 4,894,000 | 4.72% | 2026-06-30 |
| SR One Capital Management, LP | Institution (13F) | 4,615,384 | 4.45% | 2026-06-30 |
| Venrock Adviser, LLC | Institution (13F) | 4,319,765 | 4.17% | 2026-06-30 |
| NEA Management Company, LLC | Institution (13F) | 4,118,621 | 3.97% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,951,169 | 3.81% | 2026-06-30 |
| Jacob Chacko PRESIDENT AND CEO, Director · +1.39M options |
Insider | 581,711 | 0.56% | 2025-12-15 |
| Richard A. Heyman Director · +157,453 options |
Insider | 244,972 | 0.24% | 2026-07-24 |
Share count 103,652,656 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-28 filed 2026-09-29 |
Piscitelli Dominic |
Option exercise (M) | 13,400 | $4.36 | 83,228 |
| 2026-09-28 filed 2026-09-29 |
Piscitelli Dominic |
Sale (S) | 13,400 | $13.53 | 69,828 |
| 2026-09-28 filed 2026-09-29 |
Piscitelli Dominic |
Option exercise (M) | 13,400 | – | – |
| 2026-09-24 filed 2026-09-25 |
Piscitelli Dominic |
Sale (S) | 500 | $13.51 | 69,828 |
| 2026-09-24 filed 2026-09-25 |
Piscitelli Dominic |
Option exercise (M) | 600 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORIC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →